Bio

Mike is passionate about improving healthcare, developing talent, and driving business performance. He has worked at the convergence of science, digital, and technology for over 22 years. Mike leads the digital and tech organization aligned to GSK’s R&D enterprise, with a mandate to supercharge its data capability, to derive new insights from scientific data, power R&D productivity, and unlock value from digital health solutions. The team’s portfolio is engineered to reduce cycle times and help increase success rates for new vaccines and medicines. It’s technology applications span the full range of R&D functions, from Research, AI-ML, CMC as well as all activities under Development, including clinical trials, regulatory and post-approval safety and quality. His team is launching a new digital platform called Onyx which will bring sophisticated data engineering in-house to support the AI-ML and genomics teams, apply more predictive methods to medicine and vaccine discovery, and leverage real world data to inform research. Mike sponsors several areas of the overall digital transformation at GSK, including a shift to a product-centric organization, strategic partnerships with tech companies, and digital training. He is personally energized by accelerating innovation through culture and is especially motivated by building diverse teams and fostering inclusive leaders. Mike has spent his career improving healthcare using digital, data, and analytics technology. Prior to joining GSK in 2018, Mike was CIO of Quintiles before its rebranding as IQVIA and was accountable for the tech platforms used to enable clinical trials in more than 100 countries. He oversaw the company’s R&D technology strategy after the merger with IMS and Quintiles, led the product teams that built out the next generation of clinical development data and analytics capabilities, decentralized trials platforms, and supported several tech acquisitions. Mike worked at Shire pharmaceuticals for several years in IT leadership roles and also built his foundational knowledge in biopharmaceuticals and technology over 12 years as management consultant at Accenture. Mike's education is in mechanical engineering and he holds an executive MBA from London Business School.